Product Images Clopidogrel

This text provides information on the co-administration of different types of PPIs (Proton Pump Inhibitors) such as dexlansoprazole, lansoprssole, pantoprazole, and omeprazole. It presents data on the effect of these PPIs on the active metabolite AUC (area under the curve) along with mean and 90% confidence interval values. Additionally, it mentions a change relative to Plavix when administered alone.*

This data shows the cumulative event rates (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke in patients treated with placebo plus aspirin compared to clopidogrel plus aspirin. The results indicate a significant difference between the two treatment groups, with a p-value of 0.00009. Standard therapies were also used in conjunction with the treatments.*

This is a table showing data related to medication usage and outcomes for patients with a history of previous myocardial infarction (MI) or stroke. It includes information on the use of medications like Heparin/LMWH, Aspirin, GPIIb/IIIa Antagonists, Beta-Blockers, and Ace Inhibitors. The table also provides the number and percentage of patients taking Clopidogrel and Placebo, along with the respective outcomes favoring Clopidogrel or Placebo. Hazard ratios with 95% confidence intervals are also included in the table. The data appears to relate to a study or trial evaluating the effectiveness of different medications in this patient population.*

This text presents data on the Cumulative Event Rate of fatal or non-fatal vascular events for Aspirin and Clopidogrel over a period of 30 months. The event rate comparison shows a p-value of 0.045. This information can be utilized for evaluating the efficacy of these medications in preventing vascular events.*

This text presents mortality data from a placebo group and a group treated with Clopidogrel tablets. The Clopidogrel group experienced a 7% reduction in the risk of death compared to the placebo group (p = 0.03). The patients were all treated with aspirin, and monitoring was conducted for up to 28 days since randomization.*

This evaluation compares the effectiveness of Placebo and Clopidrogel Tablets in reducing the risk of death, reinfarction, or stroke before the first discharge. The study shows that Clopidrogel Tablets resulted in a 9% proportional risk reduction compared to Placebo, with statistical significance of p=0.002. The graph displays the progression over 28 days after randomization for patients who all received aspirin during treatment.*

This text appears to be a data summary of a research study or clinical trial evaluating the effects of different variables on patient outcomes. It includes information on subgroups based on gender, age, time since onset, blood pressure, heart rate, and medication given. The data also presents results in terms of percentages for different conditions or treatments. Further analysis can be done based on this information to draw conclusions regarding the impact of these factors on the overall outcome.*

This text provides data on the effectiveness of clopidogrel tablets and aspirin in patients with different conditions like stroke and PAD. The numbers next to the drug names represent the percentage of patients who received each treatment in the study. The Hazard Ratio is also mentioned but further details are not available.*